A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 05 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Jul 2012 Actual initiation date (June 2012) added as reported by ClinicalTrials.gov.